Glycomimetics Stock Today
| GLYC Stock | USD 0.26 0.02 6.82% |
PerformanceVery Weak
| Odds Of DistressVery High
|
GlycoMimetics is trading at 0.26089999 as of the 27th of February 2025, a 6.82 percent decrease since the beginning of the trading day. The stock's open price was 0.28. GlycoMimetics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 28th of January 2025 and ending today, the 27th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 10th of January 2014 | Category Healthcare | Classification Health Care |
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland. The company has 64.51 M outstanding shares of which 2.03 M shares are currently shorted by private and institutional investors with about 5.97 trading days to cover. More on GlycoMimetics
Moving against GlycoMimetics Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
GlycoMimetics Stock Highlights
| CEO | Rachel King | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsGlycoMimetics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand GlycoMimetics' financial leverage. It provides some insight into what part of GlycoMimetics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
GlycoMimetics (GLYC) is traded on NASDAQ Exchange in USA. It is located in P.O. Box 65, Monrovia, MD, United States, 21770 and employs 4 people. GlycoMimetics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 18.17 M. GlycoMimetics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 64.51 M outstanding shares of which 2.03 M shares are currently shorted by private and institutional investors with about 5.97 trading days to cover.
GlycoMimetics currently holds about 60.24 M in cash with (31.1 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.15, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check GlycoMimetics Probability Of Bankruptcy
Ownership AllocationGlycoMimetics has a total of 64.51 Million outstanding shares. 30% of GlycoMimetics outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check GlycoMimetics Ownership Details
GlycoMimetics Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| State Street Corp | 2024-12-31 | 179.3 K | |
| Northern Trust Corp | 2024-12-31 | 117 K | |
| Xtx Topco Ltd | 2024-12-31 | 64.2 K | |
| Jane Street Group Llc | 2024-12-31 | 58.9 K | |
| Intellectus Partners, Llc | 2024-12-31 | 46 K | |
| Adar1 Capital Management Llc | 2024-09-30 | 45.7 K | |
| Renaissance Technologies Corp | 2024-12-31 | 41.2 K | |
| Susquehanna International Group, Llp | 2024-12-31 | 40.8 K | |
| Ieq Capital, Llc | 2024-12-31 | 38.4 K | |
| Bvf Inc | 2024-12-31 | 9.5 M | |
| Logos Global Management Lp | 2024-12-31 | 5.4 M |
GlycoMimetics Historical Income Statement
GlycoMimetics Stock Against Markets
GlycoMimetics Corporate Executives
Elected by the shareholders, the GlycoMimetics' board of directors comprises two types of representatives: GlycoMimetics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GlycoMimetics. The board's role is to monitor GlycoMimetics' management team and ensure that shareholders' interests are well served. GlycoMimetics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GlycoMimetics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Brian Hahn | CFO and Principal Accounting Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlycoMimetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade GlycoMimetics Stock refer to our How to Trade GlycoMimetics Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlycoMimetics. If investors know GlycoMimetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlycoMimetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of GlycoMimetics is measured differently than its book value, which is the value of GlycoMimetics that is recorded on the company's balance sheet. Investors also form their own opinion of GlycoMimetics' value that differs from its market value or its book value, called intrinsic value, which is GlycoMimetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlycoMimetics' market value can be influenced by many factors that don't directly affect GlycoMimetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlycoMimetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if GlycoMimetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlycoMimetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.